Drawing for SOTIO

USPTO serial 79218559

SOTIO

Reviewed by CopyMark Law Group

Reg. 5577770Status 706Registered
Filing date
Status date
Registration date
Oct 9, 2018
Examiner
BENMAMAN, ALICE
Law office
Historical data usage

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with SOTIO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Shane Rumbaugh

Shane Rumbaugh Rumbaugh Law PLLC2400 Ansys Drive, Suite 102Canonsburg, PA 15317United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, [ medical and veterinary ] preparations for the treatment of oncological, [ immune and autoimmune ] diseases; anticancer preparations; antitumor drugs; [ vaccines; anticancer vaccines; synthetic peptides, recombinant proteins, antibodies, antibody derivatives, antibody-drug conjugates, nucleotides and nucleotide analogs all for the treatment of oncological, immune and autoimmune diseases for medical and veterinary purposes; ] biological preparations for the treatment of oncological, [ immune and autoimmune ] diseases for medical [ and veterinary ] purposes; cellular preparations for the treatment of oncological [ , immune and autoimmune ] diseases for medical [ and veterinary ] purposes [ ; biological tissue from blood or bone marrow intended for subsequent implantation; radiopharmaceutical preparations for diagnostic, medical and veterinary use; pharmaceutical preparations for the treatment of autoimmune diseases and diabetes; clinical diagnostic reagents for medical or veterinary purposes; diagnostic agents, preparations and diagnostic kits comprised of medical diagnostic reagents, sample collection devices in the nature of specimen cups and tubes, and instructions for testing of bodily fluids and tissues for use in testing and detection of oncological, immune or autoimmune diseases for medical and veterinary purposes; drug delivery agents in the form of dissolvable tablets, capsules, gels, micelles, liposomes, particles, nanoparticles, ointment and creams, that facilitate the delivery of pharmaceutical preparations; adjuvants for medical use; dietetic substances adapted for medical use, namely, food and beverages ]ACTIVE—
042Scientific services, namely, research and design in the field of antineoplastic and immunomudulating agents relating thereto; industrial analysis and research services in the field of pharmaceuticals and biotechnology; scientific research for medical [ and veterinary ] purposes in the field of oncological, [ immune and autoimmune ] diseases ; scientific research and development for medical [ and veterinary ] purposes in the area of cancerous diseases, [ autoimmune diseases or diabetes; ] pharmaceutical drug development services; conducting clinical trials for others; preclinical and clinical research in the field of oncological [ , immune and autoimmune ] diseases; analysis of toxicology and mode of action of biologicals, chemicals and combinations on animals, namely, toxicology services; pharmaceutical and biological product research, development, safety, efficacy and quality control testing services; scientific research and development for diagnostic purposes [ ; computer-aided diagnostic testing services, namely, providing reagent sample testing and diagnostic services for others in the fields of science and research related thereto; design and development of computer software and databases; design and development of computer software and databases for logistics, supply chain management and laboratory management in the fields of oncology and autoimmune disease and cancer and autoimmune research ]ACTIVE—
044Medical services; medical diagnostic services for diagnostic or treatment purposesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 18, 2026INPRPARTIAL INVALIDATION OF REG EXT PROTECTION CREATED—
Aug 5, 2025TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Aug 5, 2025ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Aug 5, 2025REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Jul 18, 2025NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jul 18, 202571AGREGISTERED-SEC.71 ACCEPTED—
Jul 14, 2025APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Apr 9, 2025ES71TEAS SECTION 71 RECEIVED—
Feb 16, 2024TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Feb 16, 2024ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Feb 16, 2024REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 9, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Nov 18, 2022NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 20, 2022CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 20, 2022TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 20, 2022ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 20, 2022REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
May 20, 2022COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Feb 11, 2022CHLDCHANGE OF OWNER RECEIVED FROM IB—
Dec 3, 2021CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Dec 3, 2021TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 3, 2021ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 3, 2021REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 3, 2021COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 21, 2020NREPNEW REPRESENTATIVE AT IB RECEIVED—
Sep 18, 2019ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Sep 18, 2019REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Feb 15, 2019FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Jan 24, 2019FICSFINAL DISPOSITION NOTICE SENT TO IB—
Jan 24, 2019FIMPFINAL DISPOSITION PROCESSED—
Jan 9, 2019FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 27, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 9, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 24, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 24, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jul 20, 2018GPNXNOTIFICATION PROCESSED BY IB—
Jul 4, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 4, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 4, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Jun 21, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 15, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 15, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Jun 15, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 15, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 15, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 6, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 6, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 1, 2018ALIEASSIGNED TO LIE—
May 29, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 22, 2018ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 22, 2018REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Dec 17, 2017RFNTREFUSAL PROCESSED BY IB—
Nov 27, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Nov 27, 2017RFRRREFUSAL PROCESSED BY MPU—
Nov 14, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Nov 13, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 13, 2017DOCKASSIGNED TO EXAMINER—
Oct 24, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Oct 20, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Oct 19, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance